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Substance abuse can produce symptoms similar to other psychiatric disorders, thus confusing the diagnostic picture. This
paper attempts to elucidate how misdiagnosis in bipolar disorder might be explained by the presence of substance abuse
comorbidities. The overlap of symptoms, limited information about symptom onset, and inexperienced clinicians can result in the
misinterpretation of symptoms of substance abuse disorders for bipolar disorder. The present study found that the presence of a
substance abuse comorbidity, the polarity of last episode (depressed, manic, mixed, not otherwise speciﬁed), and the total number
of comorbidities aﬀected the reliability of a bipolar disorder diagnosis.
1.Introduction
Clinically, the symptoms of Bipolar Disorder (BPD) during
manic episodes are quite distinct and relatively easy to iden-
tify including elevated mood, rapid speech, agitation, and
participation in high-risk behaviors [1]. However, during
depressive, mixed, or hypomanic episodes, or when accom-
panied by psychotic features, BPD shares symptoms with
major depressive disorder, schizophrenia, substance abuse
disorders,andseveralpersonalitydisordersandcantherefore
be diﬃcult to distinguish.
It is this overlap in symptoms that makes the diagnostic
process challenging [2–4]. In fact, misdiagnosis is common
in BPD [5, 6]. For example, Zimmerman and colleagues [6]
examined 700 psychiatric patients who reported that they
had been previously diagnosed with BPD. Each person was
reevaluated using the Structured Clinical Interview for DSM
Disorders (SCID for DSM-IV) [7]. They found that only
43.4% of patients who claimed they had been previously
diagnosed with BPD met criteria based on the SCID. This
is consistent with other studies [5, 8].
The consequences of an incorrect diagnosis are apparent.
Treatment decisions are based on diagnosis and, therefore,
inadequate and/or incorrect pharmacological treatments
might be applied which lead to unpleasant side eﬀects
without the beneﬁt of symptom reduction [9]. These conse-
quences are costly with regard to human suﬀering and health
care service utilization [3].
In addition to overlapping symptoms, comorbidities
such as substance abuse, which occurs in 65% of those diag-
nosed with BPD [10], can produce symptoms that muddle
the diagnostic picture [11]. Goldberg and colleagues [5]
interviewed patients with substance abuse problems using
structured diagnostic interviews during substance-free time
periods. They found that only 32.9% of participants pre-
viously diagnosed with BPD met full DSM-IV criteria for
bipolar I or II disorders. This suggests that prior substance
use had contributed to the misdiagnosis. Likewise, Stewart
and El-Mallakh [12] studied patients in a substance-abuse
treatment program who had been previously diagnosed with
BPD.Theyfoundthatonly42.9%ofparticipantsmetcriteria
for BPD.
Substance abuse disorders are prevalent comorbidities
among people with BPD [13]. These disorders may begin
as primary disorders or may result from self-medication
to reduce or alleviate symptoms of BPD [14]. Commonly
abused substances include alcohol, cannabis, cocaine, and
stimulants. Not all clinicians are familiar with the signs and
symptoms of substance abuse and dependence and could
easily mistake them as evidence of a mood disorder [15]2 Depression Research and Treatment
because of their eﬀect on mood and behavior. Substance
intoxication or withdrawal symptoms may present as symp-
tomsofmaniaordepression,respectively,therebymisleading
clinicians [16]. Errors can easily occur if clinicians rely too
much on global heuristics to diagnose patients rather than
thoroughly evaluating all symptoms of a disorder [17, 18].
Studies have shown that utilizing structured diagnostic
assessments can improve diagnostic accuracy across psychi-
atric disorders (e.g., [8, 19]), but less speciﬁc guidance has
been provided regarding the mistakes made by diagnosti-
ciansandhowtheymightbeavoided.Abetterunderstanding
of common sources of error in diagnosis might provide cli-
nicians who do not have access to structured diagnostic
methods, such as the SCID, with information that improves
the accuracy of their diagnoses. For example, if prior or con-
current substance abuse or dependence is common among
patients about whom clinicians disagree on a diagnosis of
BPD, then comorbid mood symptoms and substance use
might cue the need to invest more time and eﬀort in
gathering diagnostic information. Similarly, since structured
diagnostic assessments are time intensive and costly, they
cannot be provided for all patients. If it was determined that
diagnostic error was more likely to occur for those suspected
of having BPD along with several comorbidities, then using
structured methods might be justiﬁed in these cases.
The present study reexamined diagnostic accuracy data
from Basco et al., [8] to determine if cases in which clinicians
disagreed on a diagnosis of BPD could be explained by the
presence of substance abuse or dependence, number of co-
morbidities, or polarity of last episode. Disagreements were
cases in which a primary diagnosis of BPD was given by
either a treating psychiatrist using routine clinical methods,
a nurse using the SCID, or an expert diagnostician using all
available data, but was not conﬁrmed by the other sources. It
washypothesizedthatthepresenceofsubstanceusedisorders
would lead to greater diagnostic disagreement because these
disorders would present with mood symptoms that could be
misinterpreted as a mood disorder. Additionally, the total
number of comorbidities identiﬁed by the expert or gold
standard diagnostician was compared for cases in which
diagnostic agreement was achieved between clinicians as
compared to those in which there was disagreement. It was
hypothesized that a greater number of comorbidities occur-
ring concurrently with BPD would be consistent with more
diagnostic discrepancies. Finally, the polarity of the most
recent episode was evaluated to determine if discrepancies
were more likely to occur when the patient was in a manic,
depressed, or mixed state. It was hypothesized that there
would be fewer diagnostic discrepancies when patients pre-
sented with manic symptoms than with mixed or depressive
symptoms as manic symptoms tended to be more striking
and stereotypic of the disorder.
2. Method
2.1. Sample. Participants were recruited through clinician
referrals and advertisements oﬀering free diagnostic evalua-
tion in a community mental health center. Only participants
from the Basco et al. [8] sample who had been diagnosed
Table 1: Participant demographic characteristics.
Characteristic n
Gender
Female 78
Male 43
Ethnicity
White 92
Hispanic 10
African American 18
Native American 1
Marital Status
Single, never married 27
Married 26
Divorced 41
Other 27
Education
Post-high school 43
High-school 78
with BPD by the clinic psychiatrist, study nurse (with or
without medical records), or by the expert gold standard
diagnosticians, were included in sample. This resulted in a
subsample of 120 patients aged 19 to 65 who were primarily
female and Caucasian (see Table 1). All were economically
disadvantaged and treated in a clinic for the care of persons
with severe mental illnesses. The Institutional Review Board
at the University of Texas Southwestern Medical Center at
Dallas approved the study, and all participants signed an
informed consent to participate. Participants were compen-
sated $20.00 for completion of diagnostic and follow-
up interviews. Gold standard diagnoses were explained to
patients by the expert diagnostician, and they were provided
with the opportunity to relay the diagnostic information to
their treating physician by signing a release of records form.
2.2. Procedure. At the time of his or her initial intake
evaluation at the clinic, each patient was interviewed by a
clinic psychiatrist without the use of structured diagnostic
instruments per routine clinic procedures (routine diagno-
sis). At study entry, participants underwent a Structured
Clinical Interview for DSM-IIIR (SCID) administered by a
trained psychiatric nurse. During the diagnostic interview,
the general medical history of each patient was recorded, as
well as his or her family history of mental disorders. Life
charts [20] representing a timeline of the patients’ symp-
toms, including substance use behaviors, were also con-
structed. Following the SCID, the study nurse documented
the diagnosis derived from the SCID interview (SCID diag-
nosis).
The nurse reviewed each patient’s medical records and
the SCID diagnosis was updated (SCID + medical records
diagnosis) if the additional information suggested a diﬀerent
diagnosis. Finally, an expert doctoral level diagnostician
reviewed the SCID, medical history, family mental healthDepression Research and Treatment 3
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Figure 1: Percentage of diagnostic disagreements between the
“pregold standard” diagnosis and the “gold standard” diagnosis by
the type of substance abuse that was present. ∗P<0.10, ∗∗P<0.05.
history, and life charts and conducted a follow-up interview
witheachpatienttoexplorediﬀerentialdiagnosesandtorule
out or conﬁrm the SCID + medical records diagnoses (gold
standarddiagnosis).Forthepresentstudy,theroutine,SCID,
and SCID + medical records diagnoses were combined as a
“pregold standard” diagnosis.
Because the gold standard diagnoses were assumed to be
most accurate, they were used to group patients as having
either “alcohol abuse or dependence,” “drug abuse or de-
pendence,” “alcohol and drug abuse or dependence,” or “nei-
ther alcohol nor drug abuse or dependence.” In addition, the
total number of diagnoses rendered by the “gold standard”
for each patient was recorded. In this sample, comorbidities
included substance or alcohol use disorders, panic disor-
der (with and without agoraphobia), obsessive-compulsive
disorder (OCD), generalized anxiety disorder (GAD), and
posttraumatic stress disorder (PTSD).
3. Results
Diagnostic agreement and disagreement between the “pre-
gold standard” and the “gold standard” evaluation was an-
alyzed. Chi-square tests of independence were used for all
tests below. The expected values for the chi-square tests were
obtained by averaging the proportion of agreements and
disagreements between the groups and multiplying this
average by each of the total number of observations for each
group. This was done to reduce the inﬂuence of dispropor-
tionate cell sizes.
3.1. Substance Use Disorders. The eﬀect of the presence or
absence of a substance use disorder on diagnostic agreement
and disagreement was assessed using a chi-square test with
four categories: alcohol only, drugs only, both alcohol
and drugs, and no substance use disorder (Figure 1). The
Table 2: Frequencies of substance abuse disorders.
Categories n (120) Disagreements
Alcohol abuse 29 15 (51.7%)
Alcohol abuse 4
Alcohol dependence 25
Drug abuse only 18 7 (38.9%)
Amphetamine dependence 2
Cannabis abuse or intoxication 3
Cannabis dependence 2
Cocaine abuse or intoxication 1
Cocaine dependence 1
>1t y p eo fd r u ga b u s e 1 0
Both alcohol and drug abuse 18 11 (61.1%)
Neither alcohol nor drug abuse 55 18 (32.7%)
omnibus test found marginally signiﬁcant diﬀerences in the
amount of diagnostic agreement and disagreement between
the four groups, χ2 (3, N = 120) = 6.34, P = 0.096 (see
Table 2).
A post hoc analysis revealed that there were marginally
morediagnosticdisagreementsamongpatientsinthealcohol
only group (51.7%) relative to the no substance use disorder
group (32.7%), χ2 (1, N = 84) = 3.11, P = 0.078. There were
also more diagnostic disagreements among the both alcohol
and drug group (61.1%) than the no substance use group
(32.7%), χ2 (1, N = 73) = 5.90, P<0.05. A comparison of
diagnostic disagreements between the both alcohol and drug
group (61.1%) and the drug only group (38.9%) showed no
statistical diﬀerences.
3.2. Number of Comorbidities. To test the hypothesis that
an increase in number of comorbidities would be related
to diagnostic disagreements, the numbers of comorbidities
were treated as groups and evaluated using a chi-square test.
Cochran [21] stated that chi-square tests become unreliable
when 20% of cells contain values that are less than ﬁve.
Therefore, participants with more than three comorbidities
were removed as the cell sizes were small and the expected
values for each of these groups (four = 4.05, ﬁve = 0.45,
and six = 0.45) were less than ﬁve. Therefore, the number
of diagnostic disagreements was compared for patients with
one, two, and three comorbidities (Figure 2). The number
of diagnostic disagreements showed marginally signiﬁcant
diﬀerences between the groups, χ2 (2, N = 109) = 4.89,
P = 0.087 (see Table 4).
Post hoc comparisons determined that there were mar-
ginally more diagnostic disagreements for patients with
eithertwo(52.8%),χ2 (1,N = 73) =3.05,P = 0.051,orthree
(52.1%) comorbidities, χ2 (1, N = 73) = 3.05, P = 0.081
than only one (32%) comorbidity. There was no signiﬁcant
diﬀerence in the number of diagnostic disagreements for
patients with two (52.8%) compared with three (52.1%)
comorbidities.
3.3. Polarity of Most Recent Episode. For the comparison of
agreementsanddisagreementsbythetypeofthelastepisode,4 Depression Research and Treatment
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Figure 2: Percentage of diagnostic disagreements between the “pre-
gold standard” diagnosis and the “gold standard” diagnosis by the
total number of comorbidities. ∗P<0.10.
Table 3: Frequencies of last episode type.
Categories n (120) Disagreements
Depressed 54 18 (33.3%)
Manic 23 13 (56.5%)
Mixed 19 7 (36.8%)
NOS 24 13 (54.2%)
Table 4: Frequencies of number of comorbid diagnoses.
Categories n (120) Disagreements
One 50 16 (32.0%)
Two 36 19 (52.8%)
Three 23 12 (52.2%)
Four 9 3 (33.3%)
Five 1 1 (100%)
Six 1 0 (0.00%)
patients whose last episode was Not Otherwise Speciﬁed
(NOS) were removed. An omnibus test of the inﬂuence of
the type of the most recent episode (Depressed, Manic, or
Mixed) on diagnostic disagreement revealed no signiﬁcant
diﬀerences between the groups (see Table 3). However, a
planned post hoc comparison of the number of diagnostic
disagreements for those patients whose most recent episode
was Depressed (33%) with patients whose most recent
episode was Manic (57%) found that signiﬁcantly more
diagnostic disagreements occurred for patients whose most
recent episode was Manic, χ2 (1, N = 77) = 4.18, P<
0.05 (see Figure 3). None of the other comparisons showed
statistically signiﬁcant diﬀerences.
4. Discussion
The process of assessing psychiatric diagnoses, which relies
on patient self-report of symptoms, clinical judgment, expe-
rience, and intuition to some extent, is quite complicated.
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Figure 3: Percentage of diagnostic disagreements between the “pre-
gold standard” diagnosis and the “gold standard” diagnosis by the
type of the last episode experienced. ∗∗P<0.05.
Most studies of the accuracy of diagnosis [3, 6] attest to
this. Structured methods have improved the process [8, 19],
but because of the sole reliance on clinical observation and
decision-making in the absence of available precise labora-
tory measures, even these methods are subject to error. The
purpose of this research was to attempt to identify clinical
featuresthatmightexplaindiscrepanciesindiagnosesamong
clinicians, thus providing indicators for heightened sensi-
tivity to diagnostic complexity and the potential for error.
Speciﬁcally, given the high prevalence of substance use dis-
orders among those with BPD, the association between diag-
nosticdisagreementsandthepresenceofsubstanceusedisor-
ders was evaluated. Consistent with previous studies [5, 12],
we found that there were, in fact, more diagnostic disagree-
ments for patients diagnosed with BPD who met criteria for
comorbidalcoholorsubstanceabuseordependence(alcohol
only or both alcohol and drugs) than for those who did not
have substance use disorders. These discrepancies may be
due, in part, to the fact that substance intoxication can aﬀect
mood (i.e., induce euphoria), disrupt cognitive functioning,
and lead to risk taking behaviors, all of which are common
in BPD. Withdrawal can be mistaken for symptoms of
depression such as dysphoric mood, lethargy, and sleep
disturbance. Intoxication and withdrawal can also produce
psychoticsymptomssuchashallucinations[2],whicharenot
uncommon in the depressive and manic phases of BPD.
It appears that the presence of one co-morbid psychiatric
disorder did not cloud the diagnostic picture, as it was not
associated with diagnostic disagreement. Clinicians could
diﬀerentiate one additional disorder from the primary mood
disorder. However, the presence of more than one comorbid
disorder appeared to contribute to diagnostic confusion,
most likely due to the overlap in symptoms among disorders.
Similarly, Zimmerman and colleagues [11] found that the
errors in the diagnosis of BPD occurred more frequently in
patients with three or more comorbid disorders.
The patients in this sample had comorbidities other than
substance use disorders, with anxiety disorders being the
second most common. It is not unusual for people withDepression Research and Treatment 5
BPD to also experience considerable anxiety that presents
in various forms [10]. Likewise, anxiety symptoms such
as irritability and psychomotor agitation can be present in
both the depressive and manic phases of BPD. While we
did not examine the relationship between speciﬁc anxiety
disorders and BPD diagnostic agreement, our ﬁndings on
numberofcomorbiditiesmaysuggestthatadditionalcaution
be exercised during the diagnostic process when anxiety and
BPD symptoms are present.
Past research [22, 23] has shown that substance abuse
is associated with an increased likelihood of transition in
episode polarity, a transition during which a mix of depres-
siveandmanicsymptomscanconfusethediagnosticpicture.
In addition, patients who have more than one comorbid
substance abuse disorder may have a greater variety of
mood ﬂuctuations, thus creating a complex picture that is
diﬃcult to disentangle without the opportunity to observe
the patients during periods of abstinence.
With limited time and without extensive diagnostic and
historical information, clinicians are often forced to rely on
decision-making heuristics [17, 18] as they attempt to pro-
duce the most accurate diagnosis. Unfortunately, the use of
heuristicstoformadiagnosiscanleadtosigniﬁcantmisjudg-
mentsasitreliesheavilyonpersonalpreconceptionsandpast
experiences, which are inﬂuenced by selective memory and
clinical experience that varies greatly across clinicians and
over time [3]. For example, perhaps a depression heuristic
is activated when clinicians observe symptoms of major
depression that are somewhat diﬀerent from the typical
presentation of patients with a unipolar mood disorder. In
our sample, patients with a most recent episode of major
depression were more likely to be accurately diagnosed with
BPDcomparedtothosewithamostrecentepisode ofmania.
However, overreliance on this heuristic could also lead to
inaccuracies as suggested by the ﬁnding that patients who
were abusing a depressant (i.e., alcohol) were more likely to
be incorrectly diagnosed with BPD.
4.1. Limitations. A major limitation of this research was its
sample size given that it was derived from a previous study
[8]. This limitation precluded investigation of other factors,
such as demographics, that might have been associated with
greater diagnostic disagreement. The thrust of the Basco
et al. [8] study, from which these data were derived, was that
the greater the amount of information available, the more
accurate clinicians tended to be in their evaluations. Age,
for example, can be a proxy for length of illness, with older
patients potentially having had more episodes and therefore
providing more diagnostic data for their life charts to help
distinguish substance-induced mood episodes from co-mor-
bid BPD and substance use disorders. In our sample, there
wassigniﬁcantlygreaterdiagnosticdisagreement(66.7%)for
patients under the age of 30 than for older patients (37.9%),
χ 2 (1, N = 77) = 10.06, P<0.01. This may be an arti-
fact of providing more information from which to derive a
diagnosis.
This study was also based on patients in a single mental
health center which may limit the generalizability of the
ﬁndings. Furthermore, due to the small sample size, this
study focused on diagnostic disagreements among clinicians,
not on the accuracy of the initial diagnosis (i.e., also
comparing patients who were not diagnosed with BPD who,
in fact, had BPD). Thus, we are unable to conclude that
the presence of substance abuse comorbidities increased the
likelihood of a patient with BPD not being diagnosed with
BPD. Replication of this study in diﬀerent clinical settings
with a larger sample size would help address these issues.
Additionally, the diagnoses in this study were made using
the DSM-III-R. This may raise a concern that these ﬁndings
would be diﬀerent if criteria from the DSM-IV-TR were used
instead. However, a comparison of the diagnostic criteria
for BPD in the DSM-III-R and the DSM-IV-TR found no
signiﬁcant diﬀerences. It is, therefore, believed that the re-
sults of this study are applicable to the diagnostic procedures
of the DSM-IV-TR.
For future research and elaborations on this study, it
would be of interest to study the eﬀects of individual sub-
stances on the diagnostic accuracy of BPD. Due to sample
size restrictions, comparisons were limited to a combined
level. However, if research is able to determine that the con-
sumption of a speciﬁc drug aﬀects the diagnostic reliability
of a BPD diagnosis, this will enable clinicians to identify the
exactcategoryofdrugthatcausessymptomconfusion,which
will help to simplify diagnostic procedures.
5. Conclusions
This study attempted to explain some of the factors that
might interfere with diagnostic accuracy in a community
mental health sample of patients with signiﬁcant mood
symptoms. It was found that the presence of substance abuse
or dependence, symptoms of mania, and increased number
ofcomorbiditieswererelatedtodiagnosticdisagreementsfor
bipolar disorder. These ﬁndings are not surprising. Expe-
rienced diagnosticians can attest to the fact that the more
complicated the symptom presentation, the more diﬃcult it
is to accurately disentangle symptoms, particularly when the
same symptoms are common across several disorders.
Thedrawofsubstanceuseisoftenthealterationinmood.
Itisthiseﬀectthatcontributestotheconfusioninpsychiatric
evaluations. While structured methods can help organize
diagnostic information, clinicians must still make judgments
as to the origin of symptoms (i.e., substance related or not).
What our ﬁndings suggest is that when manic symptoms
are present and a substance use history is endorsed, extra
cautionshouldbetakenincompilingadetailedhistoryofthe
onset and oﬀset of each. If substance use predates symptom
onset that is close in time, a substance-related mood disorder
diagnosisislikely.Ifself-medicationwithsubstancesofabuse
occurs after the onset of mood symptoms, then a mood
disorder may be more likely. Comorbidities are best sorted
out by use of a life chart [20] or time line where the onset
and oﬀset of BPD symptoms and substance abuse symptoms
can be documented. This method was used in the original
study to help diﬀerential diagnoses. However, when mood
and substance use symptoms occur simultaneously, it may
not be possible to diﬀerentiate the two until the patient6 Depression Research and Treatment
discontinues his or her use of substances long enough for its
eﬀect on symptoms to dissipate.
As an additional note, as the mental health community
prepares for the introduction of the DSM-V (expected in
2013), this is an opportunity to make adjustments to high-
light the importance of ruling out substance abuse disorders
when diagnosing a patient with BPD, as well as to clarify the
diﬀerences between both disorders.
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